Boehringer Ingelheim
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 5 | 3 | build underway | 8 | 11 |
| Research labs and data | 2 | claimed | claimed | 1 | 1 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
Boehringer Ingelheim scores 5 out of 10 for priority and 3 out of 10 for delivery on AI in drug discovery, with work at the build underway stage, centred on a London AI Accelerator with an anticipated £150 million over 10 years. On research labs and data it scores 2 out of 10 for priority, and delivery is shown as claimed: the company says it embeds data excellence in every step of its innovation pipeline, but the sources do not confirm a system in operation. Eight AI in drug discovery commitments were made public in the last 12 months, against one in the year before, and partners announced seven of the eight, including Variant Bio, Envisagenics, Owkin and Immunai. One research labs and data commitment was made public in the last 12 months, the renewal of a federated Trusted Research Environment with Lifebit. On 6 October 2026, 11 R&D roles were open in AI in drug discovery, including machine learning, MLOps and data engineering roles, and one lab automation role was open in research labs and data.
AI in drug discovery
What the company says: Priority 5
Anticipated £150M investment over 10 years as part of Boehringer's commitments in AI across R&D, with the first 50 AI experts in place by end of 2027
Computational science is central to our innovation strategy.
Computational Innovation (UK corporate page), 7 Apr 2026
Computational Innovation identifies and builds confidence in new therapeutic concepts and increases the likelihood of success across our portfolio.
Partnering in Computational Innovation flyer (June 2026), 18 Jun 2026, p. 1
What it shows running: Delivery 3, build underway
Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King's Cross, London, UK
Computational Innovation now has locations in Austria, Germany, UK and USA specializing in AI, machine learning, human genetics, and computational biology.
Molecule design: Leveraging AI to help create high-quality molecules faster.
Computational Innovation (UK corporate page), 7 Apr 2026
Commitments made public in the last 12 months: 8
- Variant Bio AI genomics target discovery collaboration: Variant Bio collaboration expanded from kidney into cardiovascular target discovery. Expanded, announced, 23 Sep 2026. Published by: partner release, company quoted.
- Envisagenics SpliceCore target collaboration: Multi-target collaboration and option agreement under which Envisagenics' AI-powered SpliceCore will be used to validate RNA-splicing cancer targets. New, announced, 22 Sep 2026. Published by: partner release, company quoted.
- Owkin K Pro AI Scientist and data licence: Licence to Owkin K Pro AI Scientist plus multimodal oncology and immunology data, after 2025 pilot. New, announced, 2 Sep 2026. Published by: partner only.
- Immunai single-cell AI T-cell target collaboration: Multi-project collaboration under which Immunai single-cell AI will be applied to find T-cell targets. New, announced, 25 Jun 2026. Published by: partner release, company quoted.
- London AI Accelerator (Computational Innovation UK): New London AI and ML centre in King's Cross within Computational Innovation. New, in build, 20 Apr 2026. Published by: company.
- OpenProtein.AI antibody design platform: OpenProtein.AI announced BI is broadening use of its platform after a 2025 deployment and investing in custom antibody capabilities. Expanded, announced, 31 Mar 2026. Published by: partner only.
- Galux AI protein design research agreement: Research agreement to explore AI precision protein design for therapeutics. New, announced, 17 Dec 2025. Published by: partner only.
- MOLCURE AI antibody discovery research agreement: MOLCURE multi-year research agreement applying its AI antibody platform and custom antibody LLM to BI targets. New, announced, 7 Oct 2025. Published by: partner only.
Commitments made public in the year before: 1
- Tempus oncology data and AI collaboration: New multi-year Tempus collaboration on multimodal data and AI for BI oncology R&D. New, announced, 14 May 2025. Published by: partner release, company quoted.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 11
- AI Accelerator for Drug Discovery - Talent Pool, London, UK
- ML Engineer, London, UK
- Senior ML Engineer, London, UK
- Senior Staff MLOps Engineer, London, UK
- Senior Staff AI Infrastructure Engineer, London, UK
- Senior Data Engineer, London, UK
- Senior Staff Data Engineer, London, UK
- Senior or Principal Data Engineer
- Senior Principal/ Principal Scientist, Computational Safety
- Senior or Principal Scientist of Human Genetics
- Principal Scientist, Human Genetics
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Research labs and data
What the company says: Priority 2
embedding computational biology, artificial intelligence (AI), and data excellence into every step of our innovation pipeline
Computational Innovation (UK corporate page), 7 Apr 2026
On-demand automation of multimodal, analysis-ready datasets across genomics, imaging, and clinical data.
Partnering in Computational Innovation flyer (June 2026), 18 Jun 2026, p. 1
What it shows running: Delivery claimed, claimed
embedding computational biology, artificial intelligence (AI), and data excellence into every step of our innovation pipeline
Computational Innovation (UK corporate page), 7 Apr 2026
Commitments made public in the last 12 months: 1
- Lifebit federated Trusted Research Environment: Three-year renewal of federated Trusted Research Environment used across discovery research. Renewed, operational, 1 Sep 2026. Published by: joint release.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 1
- Automation Engineer, Lab Automation, Ridgefield, CT
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Asked for as experience: Python.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- The London AI Accelerator, the Data Excellence group in Computational Innovation and the renewed federated Trusted Research Environment all work on research data pipelines. What is each one's remit, who decides on additions to them, and how are the links between them governed?
- Partners announced seven AI discovery agreements in the last 12 months, and two vendors describe a 2025 deployment or pilot that led to a broader agreement. Which function decides on evaluating and contracting external AI discovery tools (Computational Innovation, the research areas or IT), is there a set route from pilot to licence, and does the £150 million for the Accelerator fund any external tools?
Coverage limits
The search of the year before is incomplete because the 2025 Annual Press Conference slides could not be found, so results for that year are partial and not directly comparable. Regional newsrooms and German-language press and careers pages were not searched, and patents were not counted. Boehringer is not publicly listed, so there is no US annual filing, and Business Wire blocked access, so two partner releases were read from copies. Several job pages could not be opened, so some roles were classed on title and site only.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call